Studies have also explored how activating receptors GLP-1, GIP, and glucagon together may affect: Ongoing clinical trials continue evaluating long-term outcomes, maintenance dose response, and how Retatrutide compares to earlier receptor agonist compounds
Extended Data Table 2) produces more interactions with the lipids, possibly further stabilizing the open conformation of TM6, ECL3 and TM7
References Mechanism of Action 1 The activity of GHK-Cu is thought to be multifaceted and includes: GHK-Cu has been associated with the upregulation of genes involved in tissue repair, anti-inflammatory signaling, and antioxidant defense, and the downregulation of genes linked to fibrosis and oxidative stress
Reported side effects are similar to other GLP-1 type drugs mainly mild to moderate gastrointestinal symptoms like nausea or diarrhea, especially during dose escalation